SIGA Technologies Inc.
SIGA Technologies is a commercial-stage pharmaceutical company focused on health security markets in the US. Its lead product is TPOXX, an oral antiviral drug for treating human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York City.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital and an asset-light, cash-generative model.
- Return on invested capital has stayed above 15% in 5 of the last 6 years (latest 21.8%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 21.8% against a cost of capital (WACC) of 12.7%, a spread of 9.1 percentage points.
- Our discounted cash flow model points to 88% upside (target price 5.59 USD), and even our pessimistic growth scenario implies 72%: a margin of safety.
- Asset-light, cash-generative model: capital expenditure takes only 0.1% of revenue and free cash flow was positive in each of the last 6 years.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/E 9.1x vs. a median of 20.6x, P/FCF 4.9x vs. a median of 21.4x and EV/EBITDA 2.4x vs. a median of 12.9x.
Weaknesses
- Margin pressure: gross margin fell 8.9 percentage points last year, pointing to pricing pressure or rising costs.
- Deteriorating fundamentals over the last year: return on assets down 13.6 points, gross margin down 8.9 points and asset turnover down 24.1%.
- Small company (enterprise value $58 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data